Acne Vulgaris Global Market Report 2025

The acne vulgaris market size has grown strongly in recent years. It will grow from $7.94 billion in 2024 to $8.47 billion in 2025 at a compound annual growth rate (CAGR) of 6.7%. The growth during the historic period can be attributed to the increasing prevalence of acne, a growing consumer preference for natural ingredients, the expansion of online retail channels, heightened investment in research and development, and the wider availability of over-the-counter products.

The acne vulgaris market size is expected to see strong growth in the next few years. It will grow to $10.89 billion in 2029 at a compound annual growth rate (CAGR) of 6.5%. The projected growth in the forecast period can be attributed to increasing skincare awareness, a rising teenage population, a growing focus on self-care and wellness, a higher incidence of adult acne, and the expansion of telemedicine and e-commerce. Key trends during this period include technological advancements, the introduction of advanced drugs, innovative product development, increased clinical approvals, and breakthroughs in novel medical processes.

The rising demand for skincare products is expected to drive the growth of the acne vulgaris market. Skincare products are formulations designed to improve skin health and appearance, addressing various skin concerns through cleansing, moisturizing, and protection. This increasing demand is influenced by social media, growing dermatological concerns, product innovations, and a shift toward preventive skincare. Acne vulgaris treatments benefit from skincare products that target the root causes of the condition, such as excess sebum production, clogged pores, and bacterial growth. Ingredients such as salicylic acid, benzoyl peroxide, and retinoids help exfoliate the skin, reduce inflammation, and promote clearer, healthier skin. For example, in August 2024, The Cosmetic, Toiletry and Perfumery Association (CTPA), a UK-based non-profit organization, reported that the European cosmetics market reached a retail sales price (RSP) valuation of €96 billion (approximately $105 billion) in 2023, up from €88 billion (approximately $93 billion) in 2022. This highlights the increasing awareness of skincare and its role in driving the acne vulgaris market.

Leading companies in the acne vulgaris market are focusing on developing innovative solutions such as triple-combination topical treatments to offer a simplified, once-daily application for managing acne. A triple-combination topical treatment integrates three active ingredients, each addressing different aspects of a condition to enhance therapeutic effects in treating skin disorders such as acne and psoriasis. For instance, in October 2023, Bausch Health Companies Inc., a Canada-based pharmaceutical company, received approval from the Food and Drug Administration (FDA) for Cabtreo, a topical gel containing clindamycin phosphate, adapalene, and benzoyl peroxide. This formulation is designed for patients aged 12 years and older to treat acne vulgaris. By combining an antibiotic, a retinoid, and an antibacterial agent, Cabtreo effectively targets acne lesions and helps prevent future breakouts. Its convenient application method and favorable safety profile make it a viable treatment option for a broad range of patients.

In September 2023, Glenmark Specialty SA, an India-based pharmaceutical company, announced a collaboration with Cosmo Pharmaceuticals to expand its dermatology portfolio and meet the growing demand for acne treatments. This partnership aims to increase the availability of Winlevi (clascoterone cream 1%) across 15 EU countries, South Africa, and the UK, ensuring broader access to innovative acne solutions. Cosmo Pharmaceuticals NV, an Ireland-based pharmaceutical company, specializes in topical treatments for acne vulgaris.

Major players in the acne vulgaris market are Pfizer Inc., Johnson and Johnson, AbbVie Inc., L'Oréal Paris, GlaxoSmithKline Plc., Reckitt Benckiser Group plc, Viatris Inc., Teva Pharmaceuticals, Bausch Healh Companies, Sun Pharmaceutical Industries Ltd., Incyte, Aurobindo Pharma, Lupin Ltd., Torrent Pharmaceuticals, Biocon, Stiefel Laboratories, Mayne Pharma Group Limited, Paratek Pharmaceuticals, Cosmo Pharmaceuticals, AOBiome.

North America was the largest region in the acne vulgaris market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in acne vulgaris report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the acne vulgaris market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Acne vulgaris is a prevalent chronic inflammatory skin disorder that primarily affects the pilosebaceous units. It is characterized by the development of comedones, papules, pustules, nodules, and cysts, often triggered by factors such as excessive sebum production, follicular hyperkeratinization, Cutibacterium acnes proliferation, and inflammation. This condition typically appears on the face, chest, and back, varying in severity and carrying the risk of scarring.

The primary treatment types for acne vulgaris include systemic therapy, hormonal therapy, physical treatments, topical combination therapy, and others. Systemic therapy involves delivering medication through the bloodstream to treat the entire body and is commonly used for conditions such as cancer, autoimmune disorders, and infections. Treatments are categorized based on age groups, including 10 to 17 years, 18 to 44 years, 45 to 64 years, and 65 years and older. These treatments are distributed through various channels, including hospital pharmacies and online pharmacies.

The acne vulgaris market research report is one of a series of new reports that provides acne vulgaris market statistics, including acne vulgaris industry global market size, regional shares, competitors with an acne vulgaris market share, detailed acne vulgaris market segments, market trends and opportunities, and any further data you may need to thrive in the acne vulgaris industry. This acne vulgaris market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The acne vulgaris market consists of sales of topical retinoids, oral retinoids, benzoyl peroxide formulations, oral antibiotics, hormonal therapies, and salicylic acid-based treatments. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.